Icotinib is indicated for the treatment of NSCLC, particularly in patients with EGFR mutations. Icotinib was developed by Beta Pharma.
The API has now reached off-patent status, after being launched in 2011.

The information provided above is sourced from Chemrobotics PharmaVetPat https://chemroboticspharma.com/pharmVetPat
to find out more, including patent landscape and routes of synthesis, please contact our sales team.

For enquiries regarding more detailed trade data of Icotinib and many others, contact info@pharmacheminvestor.com